These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 16675450)

  • 21. Hepatitis C virus E1 recruits high-density lipoprotein to support infectivity and evade antibody recognition.
    Casiano Matos J; Harichandran K; Tang J; Sviridov DO; Sidoti Migliore G; Suzuki M; Olano LR; Hobbs A; Kumar A; Paskel MU; Bonsignori M; Dearborn AD; Remaley AT; Marcotrigiano J
    J Virol; 2024 Jan; 98(1):e0084923. PubMed ID: 38174935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single amino acid mutation of SR-BI decreases infectivity of hepatitis C virus derived from cell culture in a cell culture model.
    Gao R; Gao W; Xu G; Xu J; Ren H
    World J Gastroenterol; 2017 Jul; 23(28):5158-5166. PubMed ID: 28811710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.
    Zuiani A; Chen K; Schwarz MC; White JP; Luca VC; Fremont DH; Wang D; Evans MJ; Diamond MS
    J Virol; 2016 Dec; 90(23):10499-10512. PubMed ID: 27630236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays].
    Zhang K; Tan WJ; Deng Y; Li J; Wu XB; Ruan L
    Bing Du Xue Bao; 2008 Jul; 24(4):287-94. PubMed ID: 18780632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.
    Bankwitz D; Vieyres G; Hueging K; Bitzegeio J; Doepke M; Chhatwal P; Haid S; Catanese MT; Zeisel MB; Nicosia A; Baumert TF; Kaderali L; Pietschmann T
    J Virol; 2014 Nov; 88(21):12644-55. PubMed ID: 25142595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.
    Cowton VM; Angus AGN; Cole SJ; Markopoulou CK; Owsianka A; Dunlop JI; Gardner DE; Krey T; Patel AH
    J Virol; 2016 Aug; 90(16):7456-7468. PubMed ID: 27279607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus entry: potential receptors and their biological functions.
    Cocquerel L; Voisset C; Dubuisson J
    J Gen Virol; 2006 May; 87(Pt 5):1075-1084. PubMed ID: 16603507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies.
    Stamataki Z; Coates S; Evans MJ; Wininger M; Crawford K; Dong C; Fong YL; Chien D; Abrignani S; Balfe P; Rice CM; McKeating JA; Houghton M
    Vaccine; 2007 Nov; 25(45):7773-84. PubMed ID: 17919789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.
    Anjum S; Wahid A; Afzal MS; Albecka A; Alsaleh K; Ahmad T; Baumert TF; Wychowski C; Qadri I; Penin F; Dubuisson J
    J Infect Dis; 2013 Dec; 208(11):1888-97. PubMed ID: 23908491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission.
    Brimacombe CL; Grove J; Meredith LW; Hu K; Syder AJ; Flores MV; Timpe JM; Krieger SE; Baumert TF; Tellinghuisen TL; Wong-Staal F; Balfe P; McKeating JA
    J Virol; 2011 Jan; 85(1):596-605. PubMed ID: 20962076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.
    Vercauteren K; Van Den Eede N; Mesalam AA; Belouzard S; Catanese MT; Bankwitz D; Wong-Staal F; Cortese R; Dubuisson J; Rice CM; Pietschmann T; Leroux-Roels G; Nicosia A; Meuleman P
    Hepatology; 2014 Nov; 60(5):1508-18. PubMed ID: 24797654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins.
    Koutsoudakis G; Dragun J; Pérez-Del-Pulgar S; Coto-Llerena M; Mensa L; Crespo G; González P; Navasa M; Forns X
    PLoS One; 2012; 7(12):e52651. PubMed ID: 23300734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse Model.
    Calattini S; Fusil F; Mancip J; Dao Thi VL; Granier C; Gadot N; Scoazec JY; Zeisel MB; Baumert TF; Lavillette D; Dreux M; Cosset FL
    J Biol Chem; 2015 Sep; 290(38):23173-87. PubMed ID: 26224633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.
    Kalemera MD; Capella-Pujol J; Chumbe A; Underwood A; Bull RA; Schinkel J; Sliepen K; Grove J
    J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33147126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1.
    El-Diwany R; Cohen VJ; Mankowski MC; Wasilewski LN; Brady JK; Snider AE; Osburn WO; Murrell B; Ray SC; Bailey JR
    PLoS Pathog; 2017 Feb; 13(2):e1006235. PubMed ID: 28235087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus.
    Dreux M; Boson B; Ricard-Blum S; Molle J; Lavillette D; Bartosch B; Pécheur EI; Cosset FL
    J Biol Chem; 2007 Nov; 282(44):32357-69. PubMed ID: 17761674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The SR-BI partner PDZK1 facilitates hepatitis C virus entry.
    Eyre NS; Drummer HE; Beard MR
    PLoS Pathog; 2010 Oct; 6(10):e1001130. PubMed ID: 20949066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.
    Keck ZY; Xia J; Cai Z; Li TK; Owsianka AM; Patel AH; Luo G; Foung SK
    J Virol; 2007 Jan; 81(2):1043-7. PubMed ID: 17079294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.
    Lavillette D; Tarr AW; Voisset C; Donot P; Bartosch B; Bain C; Patel AH; Dubuisson J; Ball JK; Cosset FL
    Hepatology; 2005 Feb; 41(2):265-74. PubMed ID: 15660396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.